ArticleBulletin of experimental biology and medicine2025
The Influence of miR-802 on the Resistance of Non-Small Cell Lung Cancer and Colorectal Cancer Cells to Macrophage Cytotoxic Activity.
Article in Bulletin of experimental biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We studied the role of microRNA-802 (miR-802) in regulating the sensitivity of non-small cell lung cancer and colorectal cancer cells to the cytotoxic activity of macrophages. Previously, we demonstrated that cells resistant to macrophage-mediated effects are characterized by reduced miR-802 expression. In this study, tumor cell lines expressing miR-802 were generated, and their resistance to macrophages and proliferative activity were assessed. It was found that miR-802 expression decreases cell resistance to macrophage cytotoxicity and slows their proliferation, suggesting its potential role as a tumor suppressor. However, in cells already exhibiting a resistant phenotype, miR-802 expression is suppressed, likely through activation of epigenetic or post-transcriptional mechanisms. These results are consistent with previously published data on the dual role of miR-802 in different tumor types. Thus, miR-802 may play an important role in the development of tumor cell resistance to the immune response and could be of interest as a potential therapeutic target in immunotherapeutic approaches.
Indexed as
Identifiers
41811414What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.